Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Psychiatry/Psychology
Clinical Trials: Depression
A listing of clinical trials currently looking for volunteers to enroll in Depression studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : The University of Alabama at Birmingham, Office of Psychiatric Research
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Birmingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Birmingham : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Birmingham : Birmingham Psychiatry Pharmaceutical Studies, Inc.
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Birmingham : Birmingham Research Group
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
View More »
Birmingham : Birmingham Psychiatry Pharmaceutical Studies, Inc Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Birmingham : Birmingham Research Group Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Birmingham : Birmingham Psychiatry Pharmaceutical Studies, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Birmingham : Birmingham Psychiatry Pharmaceutical Studies, Inc.
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Birmingham : UAB
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation
Birmingham : Forest Investigative Site 036
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Birmingham : Forest Investigative Site 021
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Birmingham : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Birmingham : Birmingham Psychiatry Pharmaceutical Studies, Inc Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Dothan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Dothan : Dothan Behavioral Medicine Clinic
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Dothan : Harmonex
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Dothan : Forest Investigative Site 016
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Dothan : Forest Investigative Site 001
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Arizona
Phoenix : Dedicated Clinical Research
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Phoenix : Deidcated Clinical Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Phoenix : Dedicated Clinical Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Scottsdale : ResearchOne, Inc.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
View More »
Tucson : Genova Clinical Research Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Tucson : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Tucson : Women's Mental Health Program; University of Arizona; Department of Psychiatry
Duloxetine for Perimenopausal Depression
Tucson : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Arkansas
Fayetteville : Forest Investigative Site 027
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Little Rock : Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Little Rock : Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Little Rock : Woodland International Research Group, Inc.
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Little Rock : Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
View More »
Little Rock : K & S Professional Research Services, Llc
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Little Rock :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Little Rock : K&S Professional Research Services, LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Little Rock : Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Little Rock : Woodland International Research Inc Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Little Rock : Arkansas Psychiatric Clinic Clinical Research Trials
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Little Rock : Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
California
Arcadia : Pacific Clinical Research Medical Group
Depressed? Not Happy With Your Antidepressant?
Arcadia : Pacific Clinical Research Medical Group
Depressed? Sad? Unmotivated?
Cerritos : Comprehensive Clinical Development, Cerritos
Cerritos, CA - Depression
Cerritos : Comprehensive Clinical Development, Cerritos
Depressed? Lack of Energy? Decreased Attention?
Colton : SHANTI Clinical Trials
Depression
Encino : Pharmacology Research Institute, Encino
Studies with investigational antidepressant medications for men and women 18 years and older.
Imperial : Sun Valley Research Center
Have you been diagnosed with Depression and your current medication is not working as it should?
Imperial : Sun Valley Research Center
Patients with Major Depressive Disorder
Los Alamitos : Pharmacology Research Institute, Los Alamitos
Studies with investigational antidepressant medications for men and women 18 years and older.
Newport Beach : Pharmacology Research Institute, Newport Beach
Studies with investigational antidepressant medications for men and women 18 years and older.
Orange : Pacific Clinical Research Medical Group
Being a Kid is Hard Enough without having to deal with DEPRESSION
Orange : Pacific Clinical Research Medical Group
Depressed? Clinical Research Trial for Depression Now Enrolling in Orange, CA.
Sherman Oaks : California Neuroscience Research Medical Group, Inc.
Clinical research study of an investigational medication for Major Depressive Disorder.
Sherman Oaks : Schuster Medical Research Institute
Clinical Research Study of an investigational medication for treatment resistant Major Depressive Disorder
Sherman Oaks : Schuster Medical Research Institute
Do you suffer from Bipolar Depression?
Sherman Oaks : California Neuroscience Research Medical Group, Inc.
Research study of a study medication for Major Depressive Disorder
Sherman Oaks : Schuster Medical Research Institute
Research study of an investigational medication for Major Depression Disorder with partial response to antidepressants SSRI
Sherman Oaks, : California Neuroscience Research Medical Group, Inc.
Clinical research study of an investigational medication vs. placebo added to a
standard antidepressant treatment in persons with Major Depression.
Upland : Pacific Clinical Research Medical Group
Depressed?
Upland : Pacific Clinical Research Medical Group, Upland CA
Depressed? Sad? Clinical Trial for Depression Now Enrolling in Upland, CA
Upland : Pacific Clinical Research Medical Group
Depressed? Clinical Research Trial for Depression Now Enrolling in Upland, CA
Wildomar : Elite Clinical Trials, Inc.
Are you depressed? Do you feel like you just can't get beyond your depression?
View More »
Anaheim : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Anaheim : South Coast Medical Associates/SC Clinical Trials, Inc. Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Anaheim : South Coast Clinical Trials Inc. Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Anaheim : South Coast Clinical Trials
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Anaheim : South Coast Medical Associates/SC Clinical Trials, Inc. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Arcadia : Pacific Clinical Research Medical Group
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Arcadia : Pacific Clinical Research Medical Group
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Arcadia : US010
Efficacy Study of Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Arcadia : Pacific Clinical Research Medical Group
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Arcadia : Forest Investigative Site 050
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Arcadia : Pacific Clinical Research Medical Group
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Arcadia : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Beverly Hills : Southwest Research, Inc.
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Beverly Hills : Forest Investigative Site 009
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Beverly Hills : Forest Investigative Site 030
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Beverly Hills : Southwestern Research, Incorporated
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Beverly Hills : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Carson : AV Institue, Inc.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Carson : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Cerritos : Comprehensive NeuroScience Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cerritos : Forest Investigative Site 029
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Cerritos : Forest Investigative Site 018
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Cerritos : Comprehensive NeuroScience Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Chino : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Chino : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Chino : Catalina Research Institute, Llc
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Chino : Catalina Research Institute, Llc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Chino : Forest Investigative Site 12
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Clovis : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Colton : Shanti Clinical Trials
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Costa Mesa : ATP Clinical Research, Incorporated
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Costa Mesa : ATP Clinical Research, Incorporated
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Costa Mesa : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Costa Mesa :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Costa Mesa : Forest Investigative Site 002
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Costa Mesa : Forest Investigative Site 028
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Costa Mesa : Clinical Innovation, Inc.
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Costa Mesa : Clinical Innovations, Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Costa Mesa : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Encino : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Encino : Pharmacology Research Institute
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Encino : Pharmacology Research Institute
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Encino : Forest Investigative Site 003
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Escondido : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Escondido : Synergy Escondido
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Escondido : Synergy Clinical Research Center
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Escondido : Synergy Clinical Research Center
Major Depressive Disorder With Mixed Features - Extension
Escondido : Synergy Clinical Research of Escondido
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Garden Grove : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Garden Grove : Updated
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
Garden Grove : Collaborative Neuroscience Network, Inc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Garden Grove :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Garden Grove : Collaborative NeuroScience Network Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Garden Grove : Collaborative Neuroscience Network, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Garden Grove : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Garden Grove : Forest Investigative Site 077
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Garden Grove : Collaborative Neuroscience Network, Inc.
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Glendale : Behavioral Research Specialists, LLC
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Glendale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Glendale : Behavioral Research Specialists, Llc
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Glendale : Behavioral Research Specialists, Llc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Glendale : California Clinical Trials
Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects
Glendale : Clinical Site
Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder
Glendale : Site 103
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Glendale : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Imperial : Sun Valley Research Center
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Imperial : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Imperial : Sun Valley Behavioral Medical Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Imperial : Sun Valley Behavioral Medical Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Irvine : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Irvine : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Irvine : Irvine Center for Clinical Research
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
La Habra : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
La Habra : Omega Clinical Trials
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Los Alamitos : Pharmacology Research Institute
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Los Alamitos : Pharmacology Research Institute
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Los Alamitos : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Los Angeles : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Los Angeles : UCLA Depression Research & Clinic Program Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Mission Viejo : A.D.D. Treatment Center
International Study to Predict Optimised Treatment - in Depression
Murrieta : Forest Investigative Site 019
Safety and Efficacy of Vilazodone in Major Depressive Disorder
National City : Synergy Clinical Research Center
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
National City : Synergy Clinical Research Center
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
National City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
National City : Synergy Clinical Research Center
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
National City :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
National City : US001
Efficacy Study of Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
National City : Synergy Clinical Research Center
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
National City : Site 101
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
National City : Forest Investigative Site 019
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
National City : Synergy Clinical Research Center
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
New port Beach : Forest Investigative Site 010
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Newport Beach : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Newport Beach : Pharmacology Research Institute
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Newport Beach : Pharmacology Research Institute
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Norwalk : South Coast Clinicals
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Oakland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Oakland : Pacific Research Partners, LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Oakland : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Oakland : Pacific Research Partners
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Oceanside : North County Clinical Research
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Oceanside : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Oceanside : North County Clinical Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Oceanside : Excell Research
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Oceanside : Excell Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Oceanside : North County Clinical Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Oceanside : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Oceanside : Forest Investigative Site 039
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Oceanside : Forest Investigative Site 025
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Oceanside : Forest Investigative Site 015
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Oceanside : North County Clinical Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Orange : Pacific Clinical Research Medical Group
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Orange : Pacific Clinical Research Medical Group
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Orange : Pacific Clinical Research Medical Group
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Orange :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Orange : US007
Efficacy Study of Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Orange : Pacific Clinical Research
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Orange : Pacific Clinical Research Medical Group
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Orange : Forest Investigative Site 064
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Orange : Forest Investigative Site 043
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Orange : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Palo Alto : Stanford -VA Palo Alto Health Care System
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Palo Alto : Stanford -VA Palo Alto Health Care System
Major Depressive Disorder With Mixed Features - Extension
Paramount :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Pasadena : Pasadena Research Institute, LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Pasadena : Pasadena Research Institute, LLC
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Pico Rivera : CNRI Los Angeles LLC Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Pico Rivera : CNRI Los Angeles LLC Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Redlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Redlands : Updated
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
Redlands : Anderson Clinical Research
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Redlands : Anderson Clinical Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Redlands : Anderson Clinical Research
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Redlands : Forest Investigative Site 008
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Redlands : Forest Investigative Site 003
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Riverside : Site 113
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Riverside : Clinical Innovations, Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
San Bernardino : South Coast Clinical Trials, Inc.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
San Diego : Updated
A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
San Diego : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
San Diego : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
San Diego : Affiliated Research Institute
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Diego : Artemis Institute For Clinical Research
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Diego : Sharp Mesa Vista Hospital
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Diego : California Neuropsychopharmacology Clinical Research Inst.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Diego : Pacific Research Network, Inc
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Diego :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
San Diego : Affiliated Research Institute
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
San Diego : Clinical Innovations, Inc.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
San Diego : Sharp Mesa Vista Hospital
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
San Diego : Artemis Institute for Clinical Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
San Diego : CNRI-San Diego LLC Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
San Diego : Artemis Institute For Clinical Research
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Diego : California Neuropsychopharmacology Clinical
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Diego : Sharp Mesa Vista Hospital
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Diego : Affiliated Research Institute
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Diego : Pacific Research Network
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Diego : Artemis Institute for Clinical Research
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
San Diego : Artemis Institute for Clinical Research
Major Depressive Disorder With Mixed Features - Extension
San Diego : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
San Diego : Site 106
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
San Diego : Site 116
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
San Diego : Forest Investigative Site 006
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
San Diego : Forest Investigative Site 022
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
San Diego : PCSD - Feighner Research
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
San Diego : Affiliated Research Institute
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
San Diego : Clinical Innovations, Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
San Diego : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
San Diego : CNRI-San Diego LLC Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
San Diego : UCSD Medical Center Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
San Francisco : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Santa Ana : Clinical Innovations, Inc.
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Santa Ana : Research Across America Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Santa Ana : Neuropsychiatric Research Center of Orange County
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Santa Ana : Updated
A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
Santa Ana : Neuropsychiatric Research Center Of Orange County
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Santa Ana :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Santa Ana : Clinical Innovations Inc. Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Santa Ana : Neuropsychiatric Research Center Of Orange County
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Santa Ana : Forest Investigative Site 015
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Santa Ana : Forest Investigative Site 018
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Santa Ana : Neuropsychiatric Research Center of Orange County
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Santa Ana : Clinical Innovations Inc. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Sherman Oaks : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Sherman Oaks : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Sherman Oaks : California Neuroscience Research Medical Group, Inc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Sherman Oaks : Schuster Medical Research Institute
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Sherman Oaks : Schuster Medical Research Institute Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Sherman Oaks : California Neuroscience Research Medical Group, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Sherman Oaks : Schuster Medical Research Institute
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Sherman Oaks : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Sherman Oaks : Forest Investigative Site 066
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Sherman Oaks : Forest Investigative Site 046
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Sherman Oaks : California Neuroscience Research Medical Group, Inc
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Sherman Oaks : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Sherman Oaks : Schuster Medical Research Institute Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Stanford : Stanford University
International Study to Predict Optimised Treatment - in Depression
Stanford : Stanford University Medical Center Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Tarzana : Center for Healing the Human Spirit
International Study to Predict Optimised Treatment - in Depression
Temecula : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Temecula : Viking Clinical Research Center Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Temecula : Forest Investigative Site 011
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Temecula : Viking Clinical Research Center
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Torrance :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Torrance : US004
Efficacy Study of Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Torrance : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Torrance : Collaborative Neuroscience Network, Inc. South Bay
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Torrance : UCLA-Harbor Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Torrence : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Upland : Pacific Clinical Research Medical Group
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Upland : Pacific Clinical Research Medical Group
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Upland : Pacific Clinical Research Medical Group
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Upland : Forest Investigative Site 057
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Upland : Pacific Clinical Research Medical Group
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Wildomar : Elite Clinical Trials, Incorporated
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Wildomar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Wildomar : Elite Clinical Trials, Incorporated
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Wildomar :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Colorado
Denver : Radiant Research - Denver
Clinical Research for Depression
Denver : Radiant Research - Denver
Research Study for Depression
Denver : Radiant Research - Denver
Still Depressed?
View More »
Aurora : Forest Investigative Site 002
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Colorado Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Denver : Radiant Research, Inc.
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Denver : Western Affiliated Research Institute
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Denver : Radiant Research, Inc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Denver :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Denver : Radiant Research, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Denver : Western Affiliated Research Institute
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Denver : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Denver : Western Affiliated Research Institute
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Golden : Klein Buendel, Inc
Depression Outcomes Study of Exercise
Connecticut
Waterbury : Chase Medical Research, LLC
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.
View More »
Cromwell : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Cromwell : Connecticut Clinical Research
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Cromwell : Connecticut Clinical Research
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Cromwell : Forest Investigative Site 034
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Farmington : University of Connecticut Health Center
Study of Technology-assisted Treatment of Adolescent Depression
Hamden : Geriatric and Adult Psychiatry, LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Hartford : Hartford Hospital Institute of Living Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Middletown : Middlexex Hospital Center for Behavioral Health
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
New Britain : The Hospital of Central Connecticut, Psychiatry & Behavioral Health Research
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
New Haven : Yale Depression Research Program
Cortical GABA Concentrations in Subjects With Primary Insomnia and Depression in Partial Remission With Residual Insomnia
Norwalk :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Norwalk : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Norwich : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Norwich : Comprehensive Psychiatric Care
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Norwich : Comprehensive Psychiatric Care
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Waterbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Delaware
Wilmington : Christiana Care Health Services
Patient-Centered Depression Care for African Americans
Florida
Clearwater : Clinical Research of West Florida, Inc.
Clinical Research Study
Maitland : Florida Clinical Research Center - Orlando/Maitland
Are you Depressed?
Maitland : Florida Clinical Research Center - Orlando/Maitland
Depression getting you down?
Miami : Pharmax Research Clinic, Inc.
Depression Disorder
St. Petersburg : Comprehensive Clinical Development, St. Petersburg
Are you feeling depressed again? Feeling sad, hopeless and irritable?
St. Petersburg : Comprehensive Clinical Development, St. Petersburg
Depression
St. Petersburg : Comprehensive Clinical Development - St. Petersburg
If you are an adult struggling with depression, you may be eligible to participate in a clinical research study of an investigational medication.
St. Petersburg : Comprehensive Clinical Development - St. Petersburg
Still Depressed?
West Palm Beach : Janus Center for Psychiatric Research
Adult Depression
West Palm Beach : Janus Center for Psychiatric Research
Depression and Sexual Dysfunction
West Palm Beach : Janus Center for Psychiatric Research
Treatment-Resistant Depression
View More »
Aventura : Scientific Clinical Research, Inc. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Boca Raton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Bradenton : Florida Clinical Research Center, LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Bradenton : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Bradenton : Florida Clinical Research Center Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Brooksville : Meridien Research
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Brooksville : Meridien Research
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Clearwater : Innovative Research of West Florida, Inc. Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Clearwater : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Coral Gables : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Coral Gables : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Coral Springs : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Coral Springs : CNS Clinical Research Group
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Deerfield Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Destin : SJS Clinical Research
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Destin : SJS Clinical Research, Inc.
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Fort Lauderdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Fort Meyers : Site 112
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Fort Myers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Fort Myers : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Fort Myers : Gulfcoast Clinical Research Center
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Fort Myers :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Fort Myers : Gulfcoast Clinical Research Center
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Fort Myers : Forest Investigative Site 038
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Fort Myers : Gulfcoast Clinical Research Center
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Fort Walton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Fort Walton Beach : Emerald Coast Mood & Memory, PA
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Gainesville : Sarkis Clinical Trials
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Gainesville : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Gainesville : Sarkis Clinical Trials Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Gainesville : Sarkis Clinical Trials
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Gainsville : Forest Investigative Site 018
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Hallandale Beach : Forest Investigative Site 055
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Hialeah : Amedica Research Institute, Incorporated
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Hollywood : Scientific Clinical Research, Inc.
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Jacksonville : Clinical Neuroscience Solution, Inc.
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Jacksonville : Clinical Neuroscience Solutions, Inc.
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Jacksonville : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Jacksonville : Amit Vijapura
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Jacksonville : Clinical Neuroscience Solutions, Inc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Jacksonville :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Jacksonville : Clinical Neuroscience Solutions, Inc.
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Jacksonville : Dr. Vijapura and Assoc. Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Jacksonville : Amit Vijapura
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Jacksonville : Clinical Neuroscience Solutions, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Jacksonville : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Jacksonville : Forest Investigative Site 029
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Jacksonville : Forest Investigative Site 005
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Jacksonville : Forest Investigative Site 012
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Jacksonville : Amit Vijapura MD
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Jacksonville : Clinical Neuroscience Solutions, Inc.
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Jacksonville : Clinical Neuroscience Solutions Incorporated
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Jacksonville : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Jacksonville : Clinical Neuroscience Solutions Inc Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Jacksonville Beach : George M. Joseph, MD & Associates, Inc. Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Jacksonville Beach : Forest Investigative Site 013
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Jacksonville Beach : George M. Joseph, MD & Associates, Inc. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kissimmee : Forest Investigative Site 012
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Kissimmee : Accurate Clinical Trials, Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Lake City : Forest Investigative Site 063
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Lake City : Psychiatric Associates
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Lauderhill : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Lauderhill : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Lauderhill : Fidelity Clinical Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Lauderhill : Fidelity Clinical Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Maitland : Florida Clinical Research Center, LLC.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Maitland : US006
Efficacy Study of Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Maitland : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Maitland : Florida Clinical Research Center, LLC
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Miami :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Miami : University of Miami
International Study to Predict Optimised Treatment - in Depression
Miami : Forest Investigative Site 035
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Miami Springs : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
N. Miami : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Naranja : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
New Port Richey : Suncoast Clinical Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
North Miami : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
North Miami : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
North Miami : The Segal Institute of Clinical Research
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Oakland Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Ocala : Updated
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
Orange City :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Orlando : Ali A. Kashfi, MD
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Orlando : Clinical Neuroscience Solutions Incorporated
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Orlando : Clinical Neuroscience Solutions, Inc
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Orlando : Ali A. Kashfi, MD
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Orlando : Clinical Neuroscience Solutions Incorporated
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Orlando : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Orlando : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Orlando : Compass Research, Llc
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Orlando : Clinical Neuroscience Solutions, Inc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Orlando : Compass Research, LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Orlando : Clinical Neuroscience Solutions, Inc.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Orlando : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Orlando : Clinical Neuroscience Solutions, Inc.
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Orlando : Clinical Neuroscience Solutions, Inc. Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Orlando : Compass Research, Llc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Orlando : Clinical Neuroscience Solutions, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Orlando : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Orlando : Forest Investigative Site 026
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Orlando : Forest Investigative Site 030
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Orlando : Forest Investigative Site 004
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Orlando : Forest Investigative Site 035
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Orlando : Ali A. Kashfi, MD, PA
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Orlando : Compass Research, LLC Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Pembroke Pines : Forest Investigative Site 045
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Sanford : Medical Research Group of Central Florida
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Sanford : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Sarasota : Florida Clinical Research Center, LLC
Major Depressive Disorder With Mixed Features - Extension
St Petersburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
St Petersburg : Comprehensive Clinical Development, Inc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
St Petersburg : Comprehensive Clinical Development, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
St. Petersburg : Meridien Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
St. Petersburg : Comprehensive NeuroScience, Inc.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
St. Petersburg : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
St. Petersburg : Comprehensive NeuroScience, Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Tampa : Stedman Clinical Trials
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Tampa :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Tampa : Stedman Clinical Trials
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Tampa : University of South Florida College of Medicine Psychiatry Center
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Tampa : Stedman Clinical Trials
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Tampa : University of South Florida Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Tampa : Site 130
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Tampa : Forest Investigative Site 051
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Tampa : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Tampa : University of South Florida Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Tampa : Stedman Clinical Trials, LLC Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
West Palm Beach : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
West Palm Beach : Janus Center For Psychiatric Research
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
West Palm Beach : Janus Center for Psychiatric Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
West Palm Beach : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
West Palm Beach : Janus Center For Psychiatric Research
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
West Palm Beach : Forest Investigative Site 032
Safety and Efficacy of Vilazodone in Major Depressive Disorder
West Palm Beach : Janus Center for Psychiatric Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Winter Haven : Clinical Research of Central Florida
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Winter Park : Kolin Research Group
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Winter Park : Kolin Research Group
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Winter Park : Winter Park Memorial Hospital
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Winter Park : Kolin Research Group
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Winter Park : Site 108
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Winter Park : Forest Investigative Site 022
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Winter Park : Forest Investigative Site 013
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Winter Park : Kolin Research Group
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Winterpark : Winter Park Memorial Hospital
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Georgia
Atlanta : Comprehensive Clinical Development, Atlanta
Are you feeling depressed again? Feeling sad, hopeless, and irritable?
Atlanta : Comprehensive Clinical Development, Atlanta
Atlanta, GA - Depression
Atlanta : Mood and Anxiety Disorders Program of Emory University Updated New
Have you been feeling sad or down nearly every day over the past month?
Atlanta : Mood and Anxiety Disorders Program of Emory University
How are you feeling?
Atlanta : Comprehensive Clinical Development - Atlanta
If you're taking antidepressant medication but are still depressed, you may qualify to participate in a clinical research study evaluating an investigational add-on medication for depression.
Atlanta : PICR Clinic
Major Depressive Disorder study: taking only SSRI; Proctitis study:
bloody stool with mucus;
Stockbridge : Mood and Anxiety Disorders Program of Emory University Updated New
Have you been feeling sad or down nearly every day over the past month?
View More »
Atlanta : Atlanta Center for Medical Research
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Atlanta : Atlanta Center for Medical Research
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Atlanta : Updated
A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
Atlanta : Updated
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
Atlanta : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Atlanta : Emory University
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Atlanta : Comprehensive Clinical Development, Inc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Atlanta : Atlanta Institute Of Medicine & Research
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Atlanta : Atlanta Institute of Medicine & Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Atlanta : Atlanta Institute of Medicine and Research
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Atlanta : Atlanta Center for Medical Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Atlanta : Comprehensive Neuroscience, Inc Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Atlanta : Emory University
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Atlanta : Comprehensive Neuroscience, Inc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Atlanta : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Atlanta : Emory University
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Atlanta : Site 133
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Atlanta : Forest Investigative Site 062
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Atlanta : Forest Investigative Site 017
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Atlanta : Forest Investigative Site 012
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Atlanta : Forest Investigative Site 005
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Atlanta : Atlanta Center for Medical Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Atlanta : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Atlanta : Atlanta Center for Medical Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Marietta : Northwest Behavioral Research Center/Northwest Behavioral Medicine
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Roswell : Updated
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
Smyma : Forest Investigative Site 065
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Smyrna : Institute for Behavioral Medicine, LLC
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Smyrna : Carman Research
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Smyrna :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Smyrna : Carman Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Smyrna : Nathan Shapira, MD, Ph.D
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Smyrna : Carman Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Smyrna : Carman Research
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Smyrna : Site 128
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Smyrna : Institute for Behavioral Medicine, LLC
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Smyrna : Carman Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Smyrna : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Smyrna : Carman Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Hawaii
Honolulu : Hawaii Clinical Research Center Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Illinois
Chicago : Rush University Medical Center - Treatment Research Center
Do you suffer from Depression?
Chicago : Rush University Medical Center - Treatment Research Center
Preventing the Recurrence of Depression in Bipolar Disorder
Chicago : Chicago Research Center, Inc
This research will evaluate the safety, tolerability and efficacy of an experimental drug, Levomilnacipran, sustained release (SR) compared to placebo (inactive substance) in the potential treatment of depression in people with Major Depressive Disorder.
Skokie : Psychiatric Medicine Associates/John Zajecka, M.D.
Depression Research Study
Skokie : Psychiatric Medicine Associates/John Zajecka, M.D.
Depression Research Study for adults who are currently taking an antidepressant but still experiencing some symptoms of depression
Skokie : Rush University Medical Center - Treatment Research Center
Depression Study. A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
View More »
Chicago : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Chicago : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Chicago : Richard S. Abrams, MD- Psychiatry
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AT1)
Chicago : Colette Bostin-Gordon, MD
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AT1)
Chicago : Rush Medical College
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Chicago : Forest Investigative Site 037
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Chicago : Forest Investigative Site 050
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Chicago : Forest Investigative Site 029
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Chicago : TMS Specialists Chicago Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Evanston : Mulitple
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
Hoffman Estates : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Hoffman Estates : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Hoffman Estates : Alexian Brothers Center for Psychiatric Research
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Joliet : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Joliet : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Joliet : Joliet Center for Clinical Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Libertyville : Capstone Clinical Research
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Libertyville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Libertyville : Capstone Clinical Research
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Libertyville : Site 132
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Libertyville : Capstone Clinical Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Naperville : AMR-Baber Research Inc.
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Naperville : AMR-Baber Research Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Oak Brook : American Medical Research, Inc.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Oak Brook : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Oak Brook : American Medical Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Oak Brook : American Medical Research, Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Oakbrook Terrace : Midwest Center for Neurobehavioral Medicine Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Oakbrook Terrace : Midwest Center for Neurobehavioral Medicine Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Park Ridge : CNS - Comprehensive Neuro Science Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Park Ridge : CNS - Comprehensive Neuro Science Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Schaumburg : Site 117
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Skokie :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Skokie : Psychiatric Medicine Associates, LLC
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Vernon Hills : Sleep and Behavior Medicine Institute
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Indiana
Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Indianapolis : The Davis Clinic
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Indianapolis : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Indianapolis : Forest Investigative Site 040
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Indianapolis : Forest Investigative Site 024
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
View More »
Indianapolis : Indiana University School of Medicine Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Lafayette : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Lafayette : Alpine Clinic
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Lafayette : Alpine Clinic Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Lafayette : Alpine Clinic
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Lafayette : Forest Investigative Site 012
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Lafayette : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Lafayette : Alpine Clinic Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Newburgh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Terre Haute : Clinco
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Terre Haute : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Terre Haute : Clinco
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Terre Haute : Clinco
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Terre Haute : Clinco
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Valparaiso : Northwest Indiana Center for Clinical Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Kansas
Overland Park : Psychiatric Associates
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Overland Park : Psychiatric Associates
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Overland Park : Forest Investigative Site 004
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Overland Park : Psychiatric Associates
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Prairie Village : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
View More »
Prairie Village : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Prairie Village : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Prairie Village : Clinical Trials Technology, Inc
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Prairie Village : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Prairie Village : Clinical Trials Technology, Inc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Prairie Village : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Prairie Village : Forest Investigative Site 074
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Prairie Village : Forest Investigative Site 053
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Prairie Village : Forest Investigative Site 031
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Prairie Village : Clinical Trials Technology, Inc.
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Wichita : Heartland Research Associates, LLC Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Wichita : Updated
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
Wichita : Heartland Research Associates
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Wichita : Via Christi Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Kentucky
Lexington : Kentucky Medical Research Center
Depression
View More »
Crestview Hills : Community Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Florence : MCM Clinical Research LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Lexington : Central Kentucky Research Associates, Inc. Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Owensboro : Pedia Research, LLC
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Owensboro : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Louisiana
Lake Charles : Lake Charles Clinical Trials
Efficacy and safety study of adjunctive AZD6765 in subjects with severe Major Depressive Disorder and a history of poor response to antidepressants
Lake Charles : Lake Charles Clinical Trials
Study to assess the efficacy and safety of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorder
Lake Charles : Lake Charles Clinical Trials
Study to assess the efficacy and safety of olanzapine and fluoxetine combination versus placebo in patients ages 10 to 17 in the treatment of major depressive disorder associated with Bipolar I disorder
View More »
Lake Charles : Lake Charles Clinical Trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Lake Charles : Lake Charles Clinical Trials
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Lake Charles : Lake Charles Clinical Trials
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Lake Charles : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
New Orleans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
New Orleans : James G. Barbee, Md, Llc
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
New Orleans : James G. Barbee, Md, Llc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Shreveport : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Shreveport : Updated
A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
Shreveport : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Shreveport : J. Gary Booker, Md, Apmc
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Shreveport :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Shreveport : Louisiana Clinical Research, LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Shreveport : J. Gary Booker, Md, Apmc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Shreveport : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Maryland
Gaithersburg : Potomac Grove Clinical Research Center Updated New
An Investigational Medication for Major Depressive Disorder
Gaithersburg : Potomac Grove Clinical Research Center
Major Depressive Disorder and Sexual Dysfunction
View More »
Baltimore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Baltimore : Pharmasite Research Inc
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Baltimore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Baltimore : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Baltimore : Updated
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
Baltimore : Pharmasite Research, Inc.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Baltimore : Pharmasite Research, Inc Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Baltimore : Johns Hopkins University
Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions
Baltimore : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Baltimore : Johns Hopkins School of Medicine
Patient-Centered Depression Care for African Americans
Baltimore : Sinai Hospital
Patient-Centered Depression Care for African Americans
Baltimore : Baltimore Medical Systems, Middlesex Health Center
Patient-Centered Depression Care for African Americans
Baltimore : Johns Hopkins Community Phsyicians
Patient-Centered Depression Care for African Americans
Baltimore : Sheppard Pratt Health System
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
Baltimore : Site 110
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Baltimore : Forest Investigative Site 020
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Baltimore : Forest Investigative Site 001
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Baltimore : Pharmasite Research Inc
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Baltimore : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Gaithersburg : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Gaithersburg : Potomac Grove Clinical Research Center
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Glen Burnie : Clinical Insights
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Rockville : Neuroscientific Insights
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Rockville : Office of Marc Hertzman, MD
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Towson : Forest Investigative Site 001
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Massachusetts
Brighton : Boston Clinical Trials
Do you often feel sad, down and unmotivated?
Have you been taking medication for depression but still have symptoms?
Brighton : Boston Clinical Trials
I Feel Blue…
Brighton : Boston Clinical Trials
Stuck with Depression? You are not alone.
View More »
Belmont : Mclean Hospital
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Belmont : McLean Hospital
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Belmont : McLean Hospital
Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder (MDD) Partly Responsive to Selective Serotonin Reuptake Inhibitor (SSRI) or Selective Norepinephrine Reuptake Inhibitor (SNRI) Treatment
Belmont : Mclean Hospital
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Boston : Boston Clinical Trials Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Boston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Boston : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Boston : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Boston : Massachusetts General Hospital
Escitalopram (Lexapro) for the Treatment of Postpartum Depression
Boston : Massachusetts General Hospital
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
Boston : Massachusetts General Hospital - Center for Anxiety and Traumatic Stress Disorders
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Boston : Massachusetts General Hospital - Center for Anxiety and Traumatic Stress Disorders
Major Depressive Disorder With Mixed Features - Extension
Boston : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Boston : Depression Clinical and Research Program
Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression
Boston : Forest Investigative Site 031
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Boston : Forest Investigative Site 003
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Boston : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Boston : Massachusetts General Hospital- Depression Clinical and Research Program
Transcranial Laser Therapy for Major Depressive Disorder
Cambridge : Cambridge Health Alliance
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Cambridge : Mood and Anxiety Disorders Research Program
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Cambridge : Cambridge Health Alliance
Ropinirole in the Treatment of Bipolar Depression
Chelsea : Chelsea Counseling Center- North Suffolk Mental Health Association
Transcranial Laser Therapy for Major Depressive Disorder
Fall River : AccelRx Research
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Fall River : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Fall River : AccelRx Research
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Fall River : AccelRx Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Fall River : AccelRx Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Haverhill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Haverhill : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Watertown : Adams Clinical Trials, LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Watertown : Adams Clinical Trials LLC Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Watertown : Adams Clinical Trials LLC Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Weymouth : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Woburn : Woburn Pediatric Associates
Study of Technology-assisted Treatment of Adolescent Depression
Michigan
Ann Arbor : Michigan Head Pain and Neurological Institute Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Minnesota
Rochester : Mayo College of Medicine Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Mississippi
Flowood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Flowood : Updated
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
Flowood : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Flowood :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Flowood : Precise Research Centers Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
View More »
Flowood : Site 109
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Flowood : Forest Investigative Site 040
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Flowood : Precise Research Centers Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Missouri
St Louis : Washington University in St. Louis - Center for Clinical Studies
Are you down in the dumps with your diabetes?
St Louis : Washington University in St. Louis - Center for Clinical Studies
Depression Research Study Seeks Volunteers with Heart Failure.
St Louis : Washington University in St. Louis - Center for Clinical Studies
Pre-diabetes: Are you at risk?
View More »
Creve Coeur : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Creve Coeur : Forest Investigative Site 068
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Creve Coeur : Forest Investigative Site 011
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Creve Coeur : Forest Investigative Site 026
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Kansas City : The Center for Pharmaceutical Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
O'Fallon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
St Louis :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
St. Charles : St. Charles Psychiatric Associates - Midwest Research Group
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
St. Charles : Midwest Research Group Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
St. Charles : St. Charles Psychiatric Associates/Midwest Research Group
Major Depressive Disorder With Mixed Features - Extension
St. Charles : Midwest Research Group
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
St. Louis : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
St. Louis : Mercy Health Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
St. Louis : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
St. Louis : Mid-America Clinical Research, LLC Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
St. Louis : Mid-America Clinical Research, LLC
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
St. Louis : Washington University School of Medicine Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Nebraska
Lincoln : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Lincoln : Premier Psychiatric Research Institute, LLC
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Lincoln : Premier Psychiatric Research Institute, LLC.
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
North Platte : Heartland Pharma Development
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
North Platte : Heartland Pharma Development
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
View More »
Omaha : Quality Clinical Research, Inc. Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Omaha : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Omaha : Forest Investigative Site 007
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Omaha : University of Nebraska Medical Center Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Nevada
Las Vegas : Clinical Research Center of Nevada
Diagnosed with Depression?
View More »
Las Vegas : Center for Psychiatry and Behavioral Medicine, Incorporated
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Las Vegas : Center for Psychiatry and Behavioral Medicine, Incorporated
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Las Vegas : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Las Vegas : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Las Vegas : Clinical Research Consortium
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
New Hampshire
New Jersey
Cherry Hill : Center For Emotional Fitness
DEPRESSION
Mount Laurel : CRI WW
Do you or a loved one suffer from Depression?
New Brunswick : UMDNJ-Robert Wood Johnson Medical School
Coping With Depression in Parkinson's Disease
View More »
Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Berlin : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Cherry Hill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Cherry Hill :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Cherry Hill : Forest Investigative Site 061
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Cherry Hill : Forest Investigative Site 023
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Cherry Hill : Center for Emotional Fitness
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Cherry Hill : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Cherry Hill : Center for Mood Disorders and Neuromodulation Therapies, UMDNJ-SOM Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Marlton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Mount Laurel : CRI Worldwide, LLC Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Mount Laurel : CRI Worldwide, LLC Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Toms River : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Toms River : Bio Behavioral Health
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Toms River : Bio Behavioral Health
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Toms River : Bio Behavioral Health
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Toms River : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Toms River : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Voorhees : Amita Talati- MD
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AT1)
Willingboro : CRI Worldwide, LLC
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Willingboro : CNS Research Institute (CRI)
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Willingboro : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Willingboro : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Willingboro : Forest Investigative Site 038
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Willingboro : Forest Investigative Site 024
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Willingboro : Forest Investigative Site 014
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Willingboro : CRI Worldwide LLC
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Willingboro : CRI Worldwide
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
New Mexico
Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Albuquerque : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Albuquerque : Albuquerque Neuroscience, Inc.
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Albuquerque : Albequerque Neuroscience Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Albuquerque : Albuquerque Neuroscience, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
View More »
Albuquerque : Forest Investigative Site 010
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Albuquerque : Forest Investigative Site 011
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Albuquerque : Forest Investigative Site 006
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
New York
Bronx : Biomedical Research Alliance of New York
Major Depressive Disorder
Fresh Meadows : Comprehensive Clinical Development - Queens, NY
Still Depressed?
Holliswood : Comprehensive Clinical Development, Queens, NY
Holliswood, NY - Depression
New York : Mount Sinai Medical Center
A Functional Magnetic Resonance Investigation of Ketamine in Treatment-Resistant Major Depression
New York : Medical & Behavioral Health Research, PC
Bipolar Depression
New York : Medical & Behavioral Health Research, PC
Bipolar Depression Research Study
New York : Medical & Behavioral Health Research, PC
Depressed?
New York : Medical & Behavioral Health Research, PC Updated New
DEPRESSED? 18-65 YEARS OLD?
New York : Biomedical Research Alliance of New York Updated New
Major Depressive Disorder
View More »
Bronx : Montefiore Medical Center
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Brooklyn : Social Psychiatry Research Institute Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Brooklyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Brooklyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Brooklyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Brooklyn : Social Psychiatry Research Institute
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Brooklyn : Brooklyn Medical Institute
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Brooklyn : US014
Efficacy Study of Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Brooklyn : Social Psychiatry Research Institute Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Brooklyn : Behavioral Medical Research of Brooklyn Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Brooklyn : Social Psychiatry Research Institute
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Brooklyn : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Brooklyn : Forest Investigative Site 004
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Brooklyn : Forest Investigative Site 003
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Brooklyn : Social Psychiatry Research Institute
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Brooklyn : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Brooklyn : Behavioral Medical Research of Brooklyn Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cedarhurst : Updated
A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
Cedarhurst : Neurobehavioral Research, Inc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Cedarhurst :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Cedarhurst : Neurobehavioral Research, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Cedarhurst : Forest Investigative Site 007
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Cedarhurst : Neurobehavioral Research, Inc
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Fresh Meadows : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Fresh Meadows : Comprehensive Clinical Development, Inc
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Fresh Meadows : Comprehensive Clinical Development, Inc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Fresh Meadows : Comprehensive Clinical Development, Inc.
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Glen Oaks : The Zucker Hillside Hospital
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Mount Kisco : Bioscience Research, LLC.
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Mount Kisco : Bioscience Research, LLC.
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Mount Kisco : Bioscience Research, Llc
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Mount Kisco : Bioscience Research, Llc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Mount Kisco : Forest Investigative Site 037
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Mt. Kisco : Bioscience Research, LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Mt. Kisco : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
New York : Mount Sinai School of Medicine
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
New York : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
New York : Updated
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
New York : Depression Evaluation Service (DES), New York State Psychiatric Institute, Columbia University Department of Psychiatry
Desvenlafaxine vs. Placebo Treatment of Chronic Depression
New York : New York State Psychiatric Institute/Columbus Circle Midtown
Desvenlafaxine vs. Placebo Treatment of Chronic Depression
New York : Village Clinical Research, Inc.
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
New York :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
New York : Fieve Clinical Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
New York : Medical & Behavioral Health Research, PC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
New York : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
New York : US013
Efficacy Study of Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
New York : Medical and Behavioral Health Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
New York : Weill Medical College of Cornell University
Lexapro for Major Depression in Patients With Epilepsy
New York : Village Clinical Research, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
New York : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
New York : Weill Cornell Medical College
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
New York : Jan Roda, MD - Psychiatry
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AT1)
New York : Site 115
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
New York : Forest Investigative Site 067
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
New York : Forest Investigative Site 047
Safety and Efficacy of Vilazodone in Major Depressive Disorder
New York : Forest Investigative Site 025
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
New York : Clinlabs, Inc.
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
New York : Eastside Comprehensive Medical Center, LLC
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
New York : Medical and Behavioral Health Research Pc
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
New York : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
New York : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
New York : Fieve Clinical Services, Inc. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
New York : Medical and Behavioral Health Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
New York : Mount Sinai School of Medicine Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
NYC : Eastside Comprehensive Medical Center
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Rochester : Finger Lakes Clinical Research
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Rochester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Rochester : Finger Lakes Clinical Research
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Rochester : Research Site
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
Rochester : Updated
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
Rochester : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Rochester : Finger Lakes Clinical Research
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Rochester : Finger Lakes Clinical Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Rochester : Finger Lakes Clinical Research
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Rochester : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Staten Island : Behavioral Medical Research of Staten Island
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Staten Island : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Staten Island : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Staten Island : Richmond Behavioral Associates
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Staten Island : Behavioral Medical Research of Staten Island Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Staten Island : Richmond Behavioral Associates Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Staten Island : Behavioral Medical Research of Staten Island
Major Depressive Disorder With Mixed Features - Extension
Staten Island : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Staten Island : Behavioral Medical Research of Staten Island Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Staten Island : Richmond Behavioral Associates Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Stony Brook : Stony Brook University Medical Center
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Syracuse : Suny Upstate Medical University
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
White Plains : Weill Cornell Medical College
International Study to Predict Optimised Treatment - in Depression
White Plains : Weill Cornell Medical College-Westchester Division
Treatment Response of Geriatric Depression
North Carolina
High Point : High Point Clinical Trials Center
Are you Depressed, Overweight and taking an antidepressant?
View More »
Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Charlotte : Carolinas Healthcare System
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Charlotte : Carolinas Healthcare System
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Durham : Triangle Neuropsychiatry
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Durham : Psychiatry and Behavioral Sciences, Duke
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Durham : Psychiatry and Behavioral Sciences, Duke
Major Depressive Disorder With Mixed Features - Extension
Durham : Forest Investigative Site 004
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Durham : Duke University Brain Stimulation and Neurophysiology Center Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Greensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Raleigh : Richard H. Weisler, Md, Pa & Assoc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Raleigh :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Raleigh : Rcihard H. Weisler, MD, PA & Associates
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Raleigh : Richard H. Weisler, M.D. and Associates
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Raleigh : Richard Weisler, MD and Associates Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Raleigh : Richard H. Weisler, Md, Pa & Assoc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Wilmington : PMG Research of Wilmington Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Winston Salem : Wake Forest University Medical Center Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
North Dakota
Fargo : Odyssey Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Fargo : Plains Medical Clinic
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Fargo : Prairie St. Johns Clinic - Fargo
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Ohio
Cincinnati : Community Research
Feeling Depressed?
Cincinnati : Community Research
Not seeing the results you want from your antidepressant?
Toledo : Neurology & Neuroscience Center of Ohio
DEPRESSION (Not Responding to Medication) TREATMENT-RESISTANT DEPRESSION
Toledo : Neurology & Neuroscience Center of Ohio
Depression with Pain
Toledo : Neurology & Neuroscience Center of Ohio
Do You Suffer From DEPRESSION?
View More »
Avon lake : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Avon Lake : Quest Therapeutics Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Beachwood : Northcoast Clinical Trials, Inc
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Beachwood : NorthCoast Clinical Trials, Inc.
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Beachwood : Charak Clinical Research Center Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Beachwood : Northcoast Clinical Trials, Inc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Beachwood : Site 126
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Beachwood : NorthCoast Clinical Trials Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Beachwood : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Beachwood : North Coast Clinical Trials, Inc. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Canton : Neuro-Behvioral Clinical Research, Inc.
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Canton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Canton : Neuro-Behavioral Clinical Research, Inc
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Canton : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Canton : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Canton : Neuro-Behavioral Clinical Research, Inc Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Canton : Forest Investigative Site 047
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Canton : Forest Investigative Site 036
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Canton : Neuro-Behavioral Clinical Research, Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Canton : Neuro-Behavioral Clinical Research, Inc Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cincinatti : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Cincinatti : Community Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Cincinnati : Community Research
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Cincinnati : University of Cincinnati Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Cincinnati : Patient Priority Clinical Sites, Llc
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Cincinnati : Patient Priority Clinical Sites, LLC
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Cincinnati : University of Cincinnati Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cincinnati : Patient Priority Clinical Sites, Llc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Cincinnati : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Cincinnati : Site 127
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Cincinnati : Forest Investigative Site 039
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Cincinnati : Patient Priority Clinical Sites, LLC
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Cincinnati : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Cincinnati : University of Cincinnati Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cleveland : University Hospitals Case Medical Center
Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance
Cleveland : Forest Investigative Site 002
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Columbus : Radiant Research, Inc. Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Columbus : Ohio State University
International Study to Predict Optimised Treatment - in Depression
Dayton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Dayton : Midwest Clinical Research Center Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Dayton : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Dayton : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Dayton : Midwest Clinical Research Center
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Dayton :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Dayton : Midwest Clinical Research Center Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Dayton : Midwest Clinical Research Center
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Dayton : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Dayton : Forest Investigative Site 021
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Dayton : Forest Investigative Site 002
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Dayton : Forest Investigative Site 008
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Dayton : Midwest Clinical Research Center
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Garfield Heights : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Mason : Lindner Center of HOPE
Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression
Mason : Lindner Center of HOPE
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Mason : Lindner Center of HOP
Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression
Middleburg Heights : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Middleburg Heights : North Star Medical Research, LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Middleburg Heights : North Star Medical Research, LLC
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Middleburg Heights : Site 124
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Toledo : Neurology and Neuroscience Center of Ohio
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Toledo : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Toledo : Neurology & Neuroscience Center Of Ohio
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Toledo : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Toledo : Kettlie Joseph Daniels, MD Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Toledo : Neurology & Neuroscience Center Of Ohio
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Toledo : Neurology & Neuroscience Center of Ohio
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Toledo : Kettlie Joseph Daniels, MD Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Oklahoma
Enid : Cutting Edge Research of Enid
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Oklahoma City : Cutting Edge Research Group
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Oklahoma City : IPS Research Company
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Oklahoma City : SP Research, PLLC
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
View More »
Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Oklahoma City : Cutting Edge Research of Enid
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Oklahoma City : IPS Research Company
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Oklahoma City : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Oklahoma City : Ips Research Company
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Oklahoma City :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Oklahoma City : Sooner Clinical Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Oklahoma City : SP Research, PLLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Oklahoma City : IPS Research Company Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Oklahoma City : Lynn Health Science Institute Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Oklahoma City : Sooner Clinical Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Oklahoma City : Ips Research Company
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Oklahoma City : Forest Investigative Site 048
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Oklahoma City : Forest Investigative Site 042
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Oklahoma City : Forest Investigative Site 012
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Oklahoma City : IPS Research Company
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Oklahoma City : Cutting Edge Research Group
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Oklahoma City : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Oklahoma City : Lynn Health Science Institute Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Oklahoma City : Sooner Clinical Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Oklahoma City : IPS Research Company Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Tulsa : Tulsa Clinical Research, Llc
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Tulsa : Tulsa Clinical Research, Llc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Oregon
Portland : Summit Research Network (Oregon), Inc.
Depression Research Study
View More »
Eugene : Forest Investigative Site 072
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Medford : Sunstone Medical Research, LLC Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Portland : Summit Research Network (Oregon), Incorporated
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Portland : Summit Research Network (Oregon), Incorporated
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Portland : Oregon Health & Science University
Circadian Effects of Escitalopram
Portland : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Portland : Summit Research Network (Oregon) Inc
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Portland : Oregon Center For Clinical Investigations, Inc. (Occi, Inc)
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Portland : Summit Research Network (Oregon) Inc.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Portland : US012
Efficacy Study of Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Portland : Oregon Center for Clinical Investigations, Inc
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Portland : Summitt Research Network (Oregon)
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Portland : Summit Research Network (Oregon) Inc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Portland : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Portland : Oregon Center for Clinical Investigations, Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Portland : Summit Research Network (Oregon), Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Portland : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Salem : Oregon Center For Clinical Investigations, Inc (Occi, Inc)
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Salem : Oregon Center For Clinical Investigations, Inc (Occi, Inc)
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Salem : Forest Investigative Site 027
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Pennsylvania
Media : Suburban Research Associates
Do you suffer from Depression & Pain?
View More »
Allentown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Allentown : Lehigh Center for Clinical Research
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Allentown : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Allentown :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Allentown : Lehigh Center for Clinical Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Allentown : Lehigh Center for Clinical Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Allentown : Site 105
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Allentown : Forest Investigative Site 014
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Allentown : Forest Investigative Site 009
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Allentown : Lehigh Center for Clinical Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Allentown : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Allentown : Lehigh Center for Clinical Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Bridgeville : Paramount Clinical Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Bridgeville : Forest Investigative Site 069
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Bridgeville : Forest Investigative Site 049
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Colmar : Introspect of Buxmont, Ltd
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Jenkintown : Updated
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
Media : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Media : Suburban Research Associates
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Media :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Media : Suburban Research Associates Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Media : Suburban Research Associates
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Media : Site 123
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Media : Forest Investigative Site 010
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Media : Suburban Research Associates
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Norristown : Keystone Clinical Studies, Llc
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Norristown : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Norristown : Keystone Clinical Studies, Llc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Philadelphia : University of Pennsylvania
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Philadelphia : Belmont Center for Comprehensive Treatment
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Philadelphia : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Philadelphia : Belmont Center For Comprehensive Treatment
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Philadelphia : Thomas Jefferson University
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Philadelphia : University Of Pennsylvania
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Philadelphia : CRI Worldwide LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Philadelphia : Thomas Jefferson University
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Philadelphia : University Of Pennsylvania
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Philadelphia : Site 122
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Philadelphia : Forest Investigative Site 025
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Philadelphia : Forest Investigative Site 003
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Philadelphia : CRI Worldwide, LLC
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Philadelphia : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Philadelphia : Belmont Center for Comprehensive Treatment Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Philadelphia : University of Pennsylvania Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Pittsburgh : Updated
A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
Pittsburgh : University of Pittsburgh School of Medicine
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Pittsburgh : Mood Disorders Treatment Research Program University of Pittsburgh-Western Psychiatric Institute and Clinic Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Scranton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
West Chester : University Services
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Rhode Island
Lincoln : Lincoln Research - Rhode Island
Announcing a medical research study for adults with DEPRESSION and FATIGUE?
Lincoln : Lincoln Research - Rhode Island
depressed...? Approximately one in 10 people suffer from depression...you are not alone.
Lincoln : Lincoln Research - Rhode Island
Do you feel Depressed? Announcing a medical research study for people with depression.
Lincoln : Lincoln Research - Rhode Island
Is the burden of Depression weighing you down...despite medication?
Lincoln : Lincoln Research - Rhode Island
Suffering from bipolar depression and are depressed and on medication?
View More »
East Greenwich : Costal Medical Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
East Providence : Rhode Island Mood & Memory Research Institute
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Lincoln : Lincoln Research
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Lincoln :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Lincoln : AccelRx Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Lincoln : Lincoln Research
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Lincoln : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Lincoln : Forest Investigative Site 015
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Lincoln : Forest Investigative Site 033
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Lincoln : Lincoln Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Providence : Butler Hospital Mood Disorders Research Program, Brown Department of Psychiatry and Human Behavior Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Warwick : Omega Medical Research Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
South Carolina
Greer : Radiant Research - Greer
Clinical Research Study for Depression
Mt. Pleasant : Coastal Carolina Research Center
Volunteers who suffer from Fibromyalgia pain and also Depression are needed for a new clinical research study.
View More »
Charleston : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Charleston : Carolina Clinical Trials, Inc. Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Charleston : Medical University of South Carolina
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Charleston : MUSC Institute of Psychiatry, Brain Stimulation Lab Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Columbia : University Of South Carolina School Of Medicine
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Columbia : Carolina Clinical Research Services
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Columbia : Carolina Clinical Research Services
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Columbia : Carolina Clinical Research Services
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Columbia : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Mount Pleasant : Coastal Carolina Research Center Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
North Charleston : Medical University South Carolina Anxiety Disorder Program
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Tennessee
Memphis : Research Strategies of Memphis
To evaluate safety and efficacy of add on therapy in treatment of Major Depression Disorder
Memphis : Research Strategies of Memphis, LLC
To evaluate safety and efficacy of add on therapy in treatment of Major Depression Disorder
Nashville : Clinical Research Associates
Major Depression
View More »
Franklin : Psychiatric Consultants, Pc
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Franklin : Psychiatric Consultants, PC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Franklin : Psychiatric Consultants, Pc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Memphis : Research Strategies of Memphis, LLC
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Memphis : Clinical Neuroscience Solutions, Incorporated
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Memphis : Clinical NeuroScience Solutions, Inc.
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Memphis : Research Strategies of Memphis, LLC
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Memphis : Clinical Neuroscience Solutions, Incorporated
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Memphis : Updated
A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
Memphis : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Memphis : Clinical Neuroscience Solutions, Inc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Memphis : Clinical Neuroscience Solutions, Inc.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Memphis : Clinical Neurosciences Solutions, Inc.
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Memphis : Clinical Neuroscience Solutions, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Memphis : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Memphis : Forest Investigative Site 048
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Memphis : Forest Investigative Site 008
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Memphis : Forest Investigative Site 019
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Memphis : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Memphis : Clinical Neuroscience Solutions, Inc. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Nashville : Vanderbilt University Medical Center
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Nashville : Clinical Research Associates
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Nashville : Centerstone
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
Texas
Houston : Bayou City Research Corporation
Still Depressed?
San Antonio : Croft Group Research Center
Are you DEPRESSED?
San Antonio : Croft Group Research Center
Are you taking an antidepressant but still depressed?
San Antonio : Radiant Research - San Antonio
Clinical Research Study for Depression
San Antonio : Croft Group Research Center
Have you had several depressive episodes?
San Antonio : Radiant Research - San Antonio
Research Study for Depression
View More »
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Austin : FutureSearch Trials of Neurology Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Austin : FutureSearch Clinical Trials, L.P.
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Austin : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Austin : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Austin : Future Search Trials
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Austin : Community Clinical Research, Inc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Austin :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Austin : FutureSearch Clinical Trials, LP
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Austin : Community Clinical Research, Inc.
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Austin : FutureSearch Trials of Neurology Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Austin : Community Clinical Research, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Austin : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Austin : Site 119
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Austin : Forest Investigative Site 011
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Austin : Forest Investigative Site 024
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Austin : Forest Investigative Site 013
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Austin : FutureSearch Trials
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Austin : FutureSearch Trials of Neurology Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Dallas : FutureSearch Trials of Dallas
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study to Evaluate the Effect of Genotype on LY2216684
Dallas : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Dallas : Futuresearch Trials Of Dallas
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Dallas :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Dallas : Future Search Trials of Dallas, LP
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Dallas : KRK Medical Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Dallas : FutureSearch Trials of Dallas
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Dallas : Futuresearch Trials Of Dallas
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Dallas : FutureSearch Trials of Dallas, LP
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Dallas : Dept. of Psychiatry, UT Southwestern Medical Center
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Dallas : Dept. of Psychiatry, UT Southwestern Medical Center
Major Depressive Disorder With Mixed Features - Extension
Dallas : FutureSearch Trials of Dallas, LP
Major Depressive Disorder With Mixed Features - Extension
Dallas : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Dallas : Site 104
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Dallas : Forest Investigative Site 020
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Dallas : Forest Investigative Site 021
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Dallas : Forest Investigative Site 010
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Dallas : Forest Investigative Site 007
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Dallas : Pillar Clinical Research, LLC
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Dallas : FutureSearch Trials of Dallas
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Dallas : KRK Medical Research
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Dallas : UT Southwestern Medical Center Updated
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Desoto : Insite Clinical Research
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Desoto : Insite Clinical Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Desoto : Insite Clinical Research
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Desoto : Insite Clinical Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Friendswood : Bay Area Clinical Services Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Friendswood : Bay Area Clinical Services
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Friendswood : Bay Area Clinical Services Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Houston : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Houston : Ben Taub General Hospital
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Houston : Claghorn-Lesem Research Clinic, Ltd.
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Houston : Red Oak Psychiatry Associates
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Houston : Uthealth - Houston
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Houston :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Houston : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Houston : Red Oak Psychiatry Associates, P.A. Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Houston : Ben Taub General Hospital
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Houston : Red Oak Psychiatry Associates, Pa
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Houston : Ut Health-Houston
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Houston : Forest Investigative Site 016
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Houston : Forest Investigative Site 027
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Houston : Red Oak Psychiatry Associates, PA
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Houston : Bayou City Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Houston : Red Oak Psychiatry Associates, P.A. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Irving : University Hills Clinical Research Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Irving : University Hills Clinical Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Lake Jackson : Harvey Resnick, MD Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Lake Jackson : R/D Clinical Research, Inc. Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Lake Jackson : R D Clinical Research Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
San Antonio : Univ of Texas Helath Science Center at San Antonio
12- Week Open Label Treatment of Refractory Bipolar Depression
San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
San Antonio : Clinical Trials of Texas, Inc
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
San Antonio : Clinical Trials of Texas, Inc.
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
San Antonio : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
San Antonio : San Antonio Psychiatric Research Center
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Antonio : Clinical Trials of Texas, Inc.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
San Antonio : Forest Investigative Site 080
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
San Antonio : Forest Investigative Site 016
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
San Antonio : Forest Investigative Site 020
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
San Antonio : Forest Investigative Site 034
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
San Antonio : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Wharton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Wharton : Wharton Research Center, Inc.
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Wichita Falls : Grayline Clinical Drug Trials
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Wichita Falls : Grayline Clinical Drug Trials
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Wichita Falls : Grayline Clinical Drug Trials
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Wichita Falls : Grayline Clinical Drug Trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Wichita Falls : Grayline Clinical Drug Trials
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Wichita Falls : Grayline Clinical Drug Trials
Major Depressive Disorder With Mixed Features - Extension
Wichita Falls : Site 102
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Wichita Falls : Grayline Clinical Drug Trials
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Utah
Murray : Radiant Research - Salt Lake City
Clinical Research Opportunity for Depression
Murray : Radiant Research - Salt Lake City
Research Study for Depressiondep
Salt Lake CIty : Lifetree Clinical Research
Depression
Salt Lake CIty : Lifetree Clinical Research
Depression
Salt Lake CIty : Lifetree Clinical Research
Depression
View More »
Clinton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Clinton : Ericksen Research And Development
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Clinton : Ericksen Research and Development
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Clinton : Ericksen Research And Development
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Clinton : Forest Investigative Site 014
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Murray : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Murray : Radiant Research, Inc.
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Murray : Radiant Research, Inc.
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Murray : Radiant Research
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Murray : Radiant Research, Inc.
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Murray : Radiant Research, Inc.
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Murray : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Orem : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Orem : Aspen Clinical Research, LLC Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Salt Lake City : Fatigue Consultation Clinic Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Salt Lake City : Lifetree Clinical Research, LC Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Salt Lake City : University of Utah
Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram
Salt Lake City : Clinical Methods Llc
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Salt Lake City : Psychiatric And Behavioral Solutions
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Salt Lake City : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Salt Lake City : Clinical Methods Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Salt Lake City : Clinical Methods Llc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Salt Lake City : Psychiatric And Behavioral Solutions
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Salt Lake City : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Salt Lake City : Clinical Methods Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Vermont
Woodstock : Neuropsychiatric Associates
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Woodstock : Neuropsychiatric Associates
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Woodstock : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Virginia
Charlottesville : Charlottesville Medical Research Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Herndon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Herndon : Neuroscience, Inc
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Herndon : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Richmond : Alliance Research Group
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
View More »
Richmond : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Richmond : Alliance Research Group
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Richmond : Virginia Commonwealth University
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Richmond : Alliance Research Group Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Richmond : Alliance Research Group
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Richmond : Research Site
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Richmond : Alliance Research Group Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Roanoke : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Washington
Bellevue : Northwest Clinical Research Center
Depression
Bellevue : Northwest Clinical Research Center
Depression & Menopause
Seattle : Summit Research Network (Seattle) LLC
Depression Research Study
View More »
Bellevue : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Bellevue : Alkermes Investigational Site
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Bellevue : Northwest Clinical Research Center
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Bellevue : Northwest Clinical Research Center
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Bellevue : Northwest Clinical Research Center
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Bellevue : Northwest Clinical Research Center Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Bellevue : Northwest Clinical Research Center
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Bellevue : Forest Investigative Site 032
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Bellevue : Forest Investigative Site 005
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Bellevue : Forest Investigative Site 006
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Bellevue : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Kirkland : Eastside Therapeutic Resource
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Kirkland : Eastside Therapeutic Resource
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Kirkland :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Kirkland : Eastside Therapeutic Resource Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kirkland : Site 107
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Kirkland : Forest Investigative Site 015
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Kirkland : Eastside Therapeutic Resource
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Kirkland : Eastside Therapeutic Resource Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Seattle : Summit Research Network (Seattle) LLC
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Seattle : Summit Research Network (Seattle) LLC
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Seattle : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Seattle : Summit Research Network (Seattle) Llc
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Seattle :
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
Seattle : Summit Research Network (Seattle) LLC
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Seattle : Updated
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder
Seattle : Summit Research Network (Seattle) LLC
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Seattle : Summit Research Network (Seattle) Llc
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Seattle : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Seattle : Forest Investigative Site 013
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
Seattle : Forest Investigative Site 032
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Seattle : Summit Research Network (Seattle) LLC
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Spokane : Frontier Institute Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Spokane : Forest Investigative Site 075
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Spokane : Forest Investigative Site 054
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Spokane : Frontier Institute Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Washington, DC
Wisconsin
Brown Deer : Northbrooke Research Center
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Brown Deer : Northbrooke Research Center
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Brown Deer : Vanda Investigational Site
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Brown Deer : Research Site
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Brown Deer : Northbrooke Research Center Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
View More »
Deer Brown : Northbrooke Research Center
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Middleton : Dean Foundation for Health, Research & Education
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Middleton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Middleton : Dean Foundation For Health Research & Education
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Middleton : Dean Foundation For Health Research & Education
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Middleton : Forest Investigative Site 052
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Middleton : Dean Foundation for Health, Research and Education, Inc.
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Milwaukee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Milwaukee : Forest Investigative Site 056
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Waukesha : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Waukesha : Independent Psychiatric Consultants, Sc, Dba, Ipc Research
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Waukesha : Independent Psychiatric Consultants, Sc, Dba, Ipc Research
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Waukesha : Independent Psychiatric Consultants, SC, dba, IPC Research
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Argentina
Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Buenos Aires : INECO Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Buenos Aires : B.A. Psychiatric Research Cent Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Buenos Aires : Dr. Gregorio Hugo Sorin Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Buenos Aires : Fundación para el Tratamiento y el estudios de las enfermeda Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
View More »
Buenos Aires : Instituto FLENI Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Buenos Aires : Instituto Nacional de Psicopatología Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Buenos Aires : B.A. Psychiatric Research Cent Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Buenos Aires : Dr. Gregorio Hugo Sorin Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Buenos Aires : INECO Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Buenos Aires : Instituto FLENI Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Córdoba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Córdoba : Clinica Privada Integral de Psiquiatria "San Nicolas" SRL Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Córdoba : Sanatorio Prof. León S. Morra SA Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
La Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
La Plata : CENPIA - Centro de Estudios Neuropsiquiátricos y Psicológico Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
La Plata, Buenos Aires : Clinica Privada Neuropsiquiatrica San Agustin Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Rosario : Centro de Investigación y asistencia en Psiquiatria (CIAP) Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Rosario : Centro de Investigación y asistencia en Psiquiatria (CIAP) Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Australia
Adelaide : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Adelaide : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Brisbane : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Brisbane : Dr Tom George Medical Trials Pty Ltd Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Brisbane : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
View More »
Everton Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Glen Iris : Delmont Private Hospital
International Study to Predict Optimised Treatment - in Depression
Heidelberg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Heidelberg : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Heidelberg : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Malvern : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Malvern : Neurotherapy Victoria Clinical Trials Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Malvern : Neurotherapy Victoria Clinical Trials Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Melbourne : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Melbourne : The Alfred Hospital
International Study to Predict Optimised Treatment - in Depression
Melbourne : Swinburne University
International Study to Predict Optimised Treatment - in Depression
Melbourne : Monash Alfred Psychiatry Research Centre
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Melbourne : Northern Area Mental Health Services Northern Psychiatric R Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Nedlands : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Nedlands : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Spring Hill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Sydney : The University of New South Wales/ Black Dog Institute
A Study of Omega-3 as a Treatment for Major Depression
Sydney : The University of New South Wales/Black Dog Institute
A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression
Westmead : Brain Dynamic Centre
International Study to Predict Optimised Treatment - in Depression
Austria
Vienna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Wien : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Wien : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Belgium
Diest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Heusden-Zolder : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Liège : BE001
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Mont-Godinne : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
View More »
Uccle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Bulgaria
Bourgas : District Department of Psychiatric Disorders With Stationary Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Bourgas : District Department of Psychiatric Disorders With Stationary Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kardzhali : SPsyH Kardzhali Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Pazardjik : State Psychiatric Hospital - Pazardjik Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Pleven : Psychiatric clinic for women UMHAT "Dr. Georgi Stranski" Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
View More »
Plovdiv : ODPZS- EOOD, Plovdiv, Bulgaria Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Ruse : DistDisPsyDIU Ruse Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Sofia : MHAT Doverie Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Sofia : Psychiatric clinic, University Hospital "Alexandrovska" Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Sofia : MHAT Doverie Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Varna : MHAT - Sveta Marina Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Varna : Diagnostic Consultative Center "Tchaika" Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Canada
Kelowna, BC : Okanagan Clinical Trials
Are you depressed as a result of bipolar disorder?
Kelowna, BC : Okanagan Clinical Trials
Depression is more than just feeling blue or stressed and I just can't seem to shake it off this time
Kelowna, British Columbia : Okanagan Clinical Trials
Are you persistently sad? Do you lack the energy and motivation to do things you once enjoyed? Do you feel hopeless? You may be suffering from depression.
View More »
Bathurst : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Burlington : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Chatham : Chatham-Kent Clinical Trials Research Center
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Chatham : Site 205
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Chatham : Forest Investigative Site 101
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Edmonton : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Edmonton : Clinical Research Group Edmonton Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Edmonton : Clinical Research Group Edmonton Inc
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Edmonton : Grey Nuns Hospital Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Gatineau : Pierre-Janet Hospital Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Gatineau : Pierre-Janet Hospital
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Hamilton : Women's Health Concerns Clinic
Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women
Hamilton : Women's Health Concerns Clinic
Duloxetine for Major Depression in Peri-/Postmenopausal Women
Hamilton : St. Joseph's Healthcare, Centre for Mountain Health Services
Longitudinal Study of People Presenting for First Treatment of a Mood Disorder
Hamilton : McMaster University Medical Centre
Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
Kelowna : Okanagan Clinical Trials Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kelowna : Okanagan Clinical Trials Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Kelowna : Okanagan Clinical Trials
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Kelowna : Site 201
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Kelowna : Forest Investigative Site 102
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Kingston : Providence Care Mental Health Services Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
London : Regional Mental Health Care
Aripiprazole and Resistant Postpartum Depression
London : Regional Mental Health Care - London
Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
Medicine Hat : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Mississauga : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Mississauga : CA003
Efficacy Study of Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Mississauga : Anxiety and Mood Center Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Mississauga : Medical Research Associates Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Mississauga : Site 203
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Mississauga : Site 204
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Mississauga : Medical Research Associates Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Montreal : Hôpital Louis-H.Lafontaine
Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
Montreal : Centre de Recherche Fernand-Seguin
Effect of Antidepressants on White Matter Structure
Montreal : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Montreal : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Montreal : Centre de Recherche Fernand Seguin
Inflammatory Markers and Cognitive Function in Major Depression
Montreal : Hopital Louis-H Lafontaine Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Montreal : Hopital Louis-H Lafontaine
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Montreal : Hôpital Louis Hlafontaine Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Montreal : Immunodeficiency Service Montreal Chest Institute McGill University Health Centre
Trial of Citalopram for the Prevention of Depression
Montréal : Douglas Mental Health University Institute
Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study
Ottawa : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Penticton : Dr. Alexander McIntyre Inc. Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Penticton : Penticton Regional
Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
Penticton : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Penticton : Dr. Alexander McIntyre, Inc. Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Penticton : Site 202
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Penticton : Forest Investigative Site 103
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
Penticton : Dr. Alexander McIntyre, Inc. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Quebec : Clinique Marie Fitzbach
Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
Quebec : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Quebec : ALPHA Recherche Clinique
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Sherbrooke : Diex Research Sherbrooke Inc. Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Sherbrooke : Q&T Research Sherbrooke
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Sydney : AK Munshi Medical Inc.
Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
Sydney : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Thornhill : Canadian Centre for Clinical Trials Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Toronto : University Health Network - Toronto General Division
A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder
Toronto : University Health Network - Toronto Western Division
A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder
Toronto : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Toronto : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Toronto : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Vancouver : Copeman Neuroscience Centre
Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
Vancouver : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Vancouver : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Vancouver : CA006
Efficacy Study of Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Vancouver : University of British Columbia, Department of Psychiatry
Neurocognition and Work Productivity in Major Depressive Disorder (MDD)
Vancouver : Institute of Mental Health, University of British Columbia
What is the Antidepressant Mechanism of Action of Quetiapine in Bipolar Depression?
China
Baoding : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Beijing : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Changsha : The Second Xiangya Hospital of Central South University
A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Changsha : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Guangzhou : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
View More »
Hangzhou : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Kunming : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Nanjing : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Shanghai : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Taiyuan : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Tianjin : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Wuhan : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
XiAn : Research Site
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Colombia
Barranquilla : Centro de Investigaciones y Proyectos en Neurociencias CIPNA Investigations Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Barranquilla : Centro de Investigaciones y Proyectos en Neurociencias CIPNA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Bello : E.S.E. Hospital Mental de Antioquia Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Bogota : Centro de Investigacion y Atencion para la Salud Mental Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Bogota : Centro de Investigaciones del Sistema Nerviosa Limitada-Gr Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
View More »
Bogota : CISNE - UIC Campo Abierto
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Bogota : Centro de Investigacion y Atencion para la Salud Mental
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Cali : Hospital Mental de Antioquia
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Croatia
Rab : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Rijeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Split : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Zagreb : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Zagreb : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Czech Republic
Brno - mesto : Psychiatricka ambulance Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Brno-mesto : Psychiatricka ambulance
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Horovice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Kladno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Olomouc : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
View More »
Olomouc : Vojenska nemocnice Olomouc Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Olomouc : Vojenska nemocnice Olomouc
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Prague : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Praha : Clintrial, s.r.o. Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Praha : Psychiatry Trial s.r.o. Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Praha : Psychiatry Trial s.r.o.
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Praha : Clintrial, s.r.o.
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Usti Nad Labem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Denmark
Copenhagen : Copenhagen University Hospital, Rigshospitalet
Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder
Copenhagen : Herlev Hospital
The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients
Roskilde : The day clinic for treatment of non-psychotic disorders (Roskilde Psychiatry)
Mindfulness-based Behavioural Therapy (MIBT) Versus Psychodynamic Therapy for Patients With Major Depressive Disorder in Psychotherapeutic Day Treatment. A Randomised Clinical Pilot Trial
Estonia
Parnu : EE003
A Study of Lu AA21004 in Comparison to Agomelatine in Adults Suffering From Major Depression Who Did Not Respond Well to Previous Medication
Tallinn : EE001
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Tallinn : EE002
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Tartu : EE002
A Study of Lu AA21004 in Comparison to Agomelatine in Adults Suffering From Major Depression Who Did Not Respond Well to Previous Medication
Finland
Helsinki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Helsinki : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Helsinki : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Helsinki : FF Servies OY/ FF Reseach Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Helsinki : Helsingin kaupunki, Auroran sairaala Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
View More »
Jarvenpaa : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Jarvenpaa : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Joensuu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Kangasala : Kaivannon sairaala Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kuopio : FI006
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Kuopio : FI003
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Kuopio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Lohja : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Oulu : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Oulu : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Pori : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Seinajoki : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Tampera : FI007
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Tampere : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Tampere : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Tampere : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Turku : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Turku : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Turku : Turun psykiatripalvelu Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
France
Arcachon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Besancon : CHU Besancon - Clinical Psychaitric Department
Study of Transcranial Direct Current Stimulation (tDCS) as add-on Treatment for Resistant Major Depression
Besançon : C.H.U. Saint-Jacques - Service de Psychiatrie de l'Adulte
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Bron : C.H. Le Vinatier - EA 4166, UCB Lyon 1 - Department of Psychiatry - Service du Pr d'AMATO
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Caen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
View More »
Clermont Ferrand : C.H.U. Gabriel Montpied - Service de Psychiatrie et Psychologie Médicale - CMP A
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Colombes : Hôpital Louis Mourier
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Dijon : C.H.U. Dijon, Hôpital Général - Service de Psychiatrie et d'Addictologie
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Dole : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Dole : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Dole : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Dole : CMP/CHS du Jura Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Dole : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Dole : CMP/CHS du Jura Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Douai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Douai : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Douai : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Douai : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Elancourt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Elancourt : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Elancourt : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Fains : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Grenoble : C.H.U. de Grenoble, Hôpital sud - Département de Psychiatrie
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Jonzac : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Jonzac : Centre Hospitalier de Jonzac Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Jonzac Cedex : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Lézignan-Corbières : ASM Limoux
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Lille : Hôpital Fontan - C.H.R.U. Lille
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Limoges Cedex : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Limoges Cedex : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Marseille : C.H. Sainte Marguerite
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Montpellier : CHU - Hôpital La Colombière
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Montpellier Cedex 5 : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Montpellier Cedex 5 : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Montpellier Cedex 5 : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Nice : Hôpital Pasteur - CHU Nice
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Nimes : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Nîmes : Hopital Universitaire Caremeau-Batiment Polyvalent, Service Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Orvault : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Paris : FR
A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder
Paris : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Paris : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Paris : Hôpital Sainte Anne - Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Poitiers : C.H.U. de POITIERS
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Rennes : C.H.U. - C.H. Guillaume Régnier
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Rouen : C.H.U. Charles Nicolle - Service Hospitalo-Universitaire de Psychiatrie
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Saint-Denis : EPS de Ville Evrard - Unité de Saint-Denis
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
St Etienne cedex : CHU St Etienne - Hôpital Nord
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Toulon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Tours : CPU CHRU de Tours
BDNF Gene Polymorphism and Antidepressants Treatment
Germany
Achim : Praxis Dr. Andreas Mahler Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Achim : Praxis Dr. Andreas Mahler Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Bad Saarow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Baesweiler : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
View More »
Berlin : Charité - Universitätsmedizin Berlin Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Bochum : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Bonn : University Clinic Bonn
The Effect of Duloxetine on Interoceptive Awareness
Butzbach : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Cham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Cologne : University of Cologne Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Dresden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Dresden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Dresden : Universitatsklinikum Carl Gustav Carus Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Dresden : Universitatsklinikum Carl Gustav Carus Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Düsseldorf : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Erfurt : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Essen : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Freiburg : Universitaetsklinikum Freiburg
Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
Freiburg : University of Freiburg Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Göttingen : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Hamburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Hamburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Hannover : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Hattingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Ingolstadt : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Kandel : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Leipzig : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Leipzig : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Ludwigshafen : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Marburg : Department of Clinical Psychology and Psychotherapy, Philipps University Marburg
End-of-Life Fear in Patients With End-Stage Lung Disease (COPD)
Mittweida : Pharmakologisches Studienzentrum Chemnitz GmbH, Außenstelle Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Munich : Department of Psychiatry and Clin. Radiology, Ludwig-Maximilian-University
Somatosensory Processing in Depression
Nürnberg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Oranienburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Prien : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Schönau am Königssee : Klinikum Berchtesgadener Land, Schön Kliniken
End-of-Life Fear in Patients With End-Stage Lung Disease (COPD)
Schwerin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Wermsdorf : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Wiesbaden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Würzburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Greece
Haidari : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Thessaloniki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Tripoli : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Hungary
Balassagyarmat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Budapest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Budapest : Obudai Egeszsegugyi Centurm Kft. Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Budapest : Fovarosi Onkormanyzat Nyiro Gyula Korhaz, II. Pszichiatriai Osztaly
Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
Budapest : Processus Kft., Varoskapu Rendelo
Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
View More »
Budapest : Forras Outpatient Clinic Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Budapest : Varoskapu Outpatient Clinic Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Budapest : Obudai Egeszsegugyi Centurm Kft. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Budapest : Semmelweis University, Psychiatric Clinic Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Gyor : Petz Aladar Megyei Oktatokorhaz Pszichiatriai Osztaly Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Gyula : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Gyula : Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Pszichiatriai Osztaly
Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
Kunszentmarton : Varosi Egeszsegugyi Kozpont
Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
Nagykallo : Santha Kalman Szakkkorhaz Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Szekesfehervar : Fejer Megyei Szent Gyorgy Korhaz, Pszichiatriai Osztaly
Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
Szentes : Donatella 99 Bt.
Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
India
Ahmedabad : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Aurangabad : Shanti Nursing Home Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Bangalore : Abhava Hospital Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Bangalore : Abhaya Hospital Psychiatry
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Jaipur : Dr. Tambi's Neuropsychiatry Center Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
View More »
Jaipur : R.K. Yadav Memorial Mental Health & De-Addiction Hospital Psychiatry Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Jaipur : Mental Health Care & Research
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Jaipur : R.K. Yadav Memorial Mental Health & De-addiction Hospital
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Kanchanpalli : Shanti Nursing Home
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Kanpur : Mahendru Psychiatric Centre Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Kanpur : Mahendru Psychiatric Center
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Lucknow : Chhatrapati Shahuji Maharaj Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Lucknow : Chatrapati Shau Maharaj Medical University
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Mangalore : K.S. Hegde Medical Academy Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Mangalore : K.S. Hegde Medical Academy
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Pune : Poona Hospital & Research Center Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Pune : Poona Hospital & Research Center
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Vadodara : Brij Psychiatry Hospital & Muskaan Research Centre Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Vadodara : SBKS Medical College and Hospital, Brij Psychiatry Hospital
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Varanasi : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Vishakhapatnam : Brain Mind Behaviour Neurosciences Research Institute Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Vishakhapatnam : Brain Mind Behavior Neuroscience Research Institute
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Wardha : Mahatma Gandhi Institute of Medical Sciences Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Wardha : Mahatma Ghandi Institute of Medical Sciences
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Israel
Hod Hasharon : shalvataMHC
Double Blind Randomized Controlled, H1 Coil In Subjects With Bipolar Depression
Tel Hashomer : Sheba Medical Center, Department of psychiatry
Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder
Italy
Cagliari : IT010
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Catania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Catania : Azienda Ospedaliero Univ. Policlinico - Vittorio Emanuele Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Chieti : IT007
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Colleferro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
View More »
Ferrara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Firenze : S.O.D. of Psychiatry, A.O.U. Careggi Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Genova : IT004
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Genova : Clinica Psichiatrica (Pad. A), A.O. Ospedale San Martino Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Lido di Camaiore : IT005
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Messina : IT003
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Milano : IT012
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Naples : IT001
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Pisa : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Pisa : Centro per i disturbi del sonno Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Roma : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Roma : IT011
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Roma : Ospedale Sant'Andrea,Servizio Psichiatrico di Diagnosi e Cur Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Rome : IT008
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Siena : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Siena : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Torino : IT015
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Venezia : IT013
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Verona : IT009
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Japan
Adachi-ku : Suzuki Hospital
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Adachi-ku : Suzuki Hospital
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Aichi : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Amagasaki : Arai Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Amagasaki-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
View More »
Amagasaki-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Anan-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Anan-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Annaka-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Annaka-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Ashiya : Terauchi-Takahashi Psychiatric Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Chiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Chiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY221668412 in Patients With Major Depression Disorder
Chiyoda-ku : Iidabashi Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Fujioka-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Fujioka-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Fujisawa-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Fujisawa-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Fukaya-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Fukaya-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Fukuoka : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY221668412 in Patients With Major Depression Disorder
Fukuoka : Akasaka Kato Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Fukuoka : Ange Psychiatric Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Fukuoka : Hiro Mental Clinic Tenjinminami
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Fukuoka : Kuranari Psychiatry Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Fukuoka : Stress Care Yoshimura Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Fukuoka : Sugahara Tenjin Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Fukuoka : Imato Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Fukuoka : Medical Corporation Shinseikai Kaku Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Fukuoka : Tenjin Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Fukuoka-city : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Fukuoka-city : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Fukushima : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Fukushima : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Hachioji-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Hachioji-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Hachioji-shi : Ongata Hospital Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Hachioji-shi : Ongata Hospital
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Hatsukaichi : Fujikawa Clinic
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Hatsukaichi : Fujikawa Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Hatsukaichi-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Hatsukaichi-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Hirakata : Kuginuki Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Hiroshima : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Hiroshima : Tsuji Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Hiroshima-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Hiroshima-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Hokkaido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Hokkaido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY221668412 in Patients With Major Depression Disorder
Hyogo : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY221668412 in Patients With Major Depression Disorder
Ibaraki : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Ibaraki : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Ibaraki : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Ichikawa : Kohnodai Hospital, National Center for Global Health & Medicine
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Ichikawa-sha : Kohnodai Hp., National Center for Global Health and Medicine Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Inzai : Nippon Medical School Chiba Hokusoh Hospital
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Inzai-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Inzai-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Kanagawa : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY221668412 in Patients With Major Depression Disorder
Kanagawa : Medical Corporation Toyokokai Tawara Clinic
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Kanazawa : National Hospital Organization Kanazawa Medical Center
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Kanzaki-gun : NHO Hizen Psychiatric Center Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Kanzaki-gun : National Hospital Organization Hizen Psychiatric Center
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Katsushika-ku : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Katsushika-ku : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Katsushika-ku : Fuku Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Kawasaki : Kishiro Mental Clinic
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Kawasaki : Kishiro Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Kawasaki-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Kawasaki-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Kitakyushu : Hatakeyama Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Kitakyushu-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Kitakyushu-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Kobe : Ikeuchi Psycho Induced Internal Med.Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Kobe : Tatsuta Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Kobe-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Kobe-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Kodaira-shi : National Center of Neurology and Psychiatry Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Kodaira-shi : National Center of Neurology & Psychiatry
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Kumamoto : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Kumamoto-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Kumamoto-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Kumamoto-shi : Yuge Hospital
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Kurashiki-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Kurashiki-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Kure : Hayakawa Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Kyoto : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Kyoto : Sagaarashiyama-Tanaka Clinic
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Kyoto : Sagaarashiyama-Tanaka Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Kyoto-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Kyoto-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Minato-ku : Akasaka Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Musashino-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Musashino-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Nagano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Nagano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY221668412 in Patients With Major Depression Disorder
Nagareyama : Hida Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Nagoya : Mizuho Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Nagoya : Narumi Himawari Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Nakano-Ku : Harikae mental clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Nakano-ku : Heartcare Ginga Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Nanyo-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Nanyo-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Nara : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Noda City : Nakamoto Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Noda-City : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Noda-City : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Omuta : Shiranui Hospital
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Omuta : Shiranui Hospital
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Osaka : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Osaka-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Osaka-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Osaka-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Osaka-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Saga : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Saga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Saga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY221668412 in Patients With Major Depression Disorder
Sagamihara : Yutaka Clinic
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Sagamihara : Yutaka Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Sagamihara-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Sagamihara-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Saitama : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Saitama-city : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Saitama-city : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Saitama-city : Sakai Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Sakai-shi : Asakayama General Hospital Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Sakai-shi : Asakayama General Hospital
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Sapporo-Shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Sapporo-Shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Sapporo-Shi : Kawamura Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Setagaya-ku : Komazawa Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Setagaya-ku : Sangenjaya Nakamura Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Shibuya-ku : Maynds Tower Mental Clinic
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Shibuya-ku : Maynds Tower Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Shibuya-ku : Omotesando Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Shinagawa-ku : Meguro sta.East Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Shinjuku-ku : Tokyo Kosei Nenkin Hospital
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Shinjuku-ku : Nishi-Shinjuku Concieria Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Shinjuku-ku : Tokyo Kosei Nenkin Hospital
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Shinjuku-ku : Tamaki Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Shizuoka : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Taito-Ku : Local Institution
Japanese Phase 1 Multiple Ascending Dose (MAD) Study
Takasaki-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Takasaki-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Takatsuki : Osaka Institute of Clinical Psychiatry Shin-abuyama Hospital
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Takatsuki-shi : Osaka Institute of Clinical Psychiatry Shin-abuyama Hospital Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Tochigi : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Tokushisma-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Tokushisma-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Tokyo : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY221668412 in Patients With Major Depression Disorder
Tokyo : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Tokyo : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Tokyo : Eto Mental Clinic Meguro
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Toshima-ku : Himorogi Psychiatric Institute
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Toshima-ku : Himorogi Psychiatric Institute
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Utsunomiya-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Utsunomiya-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Yokohama : Tawara Clinic
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Yokohama : Medical Coporation Toyokokai Tawara Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Yokohama-shi : Updated
Efficacy and Safety of Lu AA21004 for Treatment of Major Depressive Disorder
Yokohama-shi : Updated
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Yokohama-Shi : Azamino Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Yokosuka city : Shioiri Mental Clinic
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Yokosuka city : Shioiri Mental Clinic
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Korea, Republic of
#50 Ilwon-dong Kangnam-gu : Samsung Medical Center
Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
Anyang : Hallym Univesity Sacred Heart Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Busan : Dong-A University Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Daegu : Dongsan Medical Center
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Goyang : Dongguk University International Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
View More »
Gwangju : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Gwangju : Chonnam National University Hospital
Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome
Gwangju : Chosun University Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Incheon : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Inchon : Inha University Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Seongnam-si : CHA Bundang Medical Center, CHA University
Study of Lu AA21004 in Major Depressive Disorder in Asian Countries
Seoul : GSK Investigational Site Updated
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Seoul : Seoul National University Hospital
Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients
Seoul : 22
Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
Seoul : KyungHee University Medical Center
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Seoul : Severance Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Seoul : Asan Medical Center
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Latvia
Daugavpils : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Jelgava : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Liepaja : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Liepaja : LV001
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Sigulda : LV003
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
View More »
Strenci : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Lithuania
Kaunas : Kaunas Hospital Division Marui Hospital, Public Institution Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Kaunas : Neuromeda, JSC Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Kaunas : Neuromeda JSC
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Kaunas : Ziegzdriai Mental Hospital, Public Institution
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Silute : Silutes Mental Health and Psychotherapy Center, JSC Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
View More »
Silute : Silutes Mental Health & Psychtherapy Center, JSC
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Vilnius : Zirmunai Mental Health Center, Public Institution Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Vilnius : Seskines Outpatient Clinic, Public Institution Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Vilnius : Zirmunai Mental Health Center, Public Institution
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Vilnius : Seskines Outpatient Clinic, Public Institution
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Mexico
Aguascalientes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Monaco
Monaco : Centre Hospitalier Princesse Grace
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Netherlands
Nijmegen : Brainclinics Diagnostics B.V.
International Study to Predict Optimised Treatment - in Depression
New Zealand
Auckland : University of Auckland
International Study to Predict Optimised Treatment - in Depression
Norway
Lorenskog : Akershus University Hospital
Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy
Skien : NO001
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Peru
Lima : Clinica Vesalio Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Lima : Hospital Nacional Arzobispo Loayza Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Lima : Hospital Nacional Hipolito Unanue Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Lima : Hospital Nacional Hipolito Unanue
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Lima : Clinica Vesalio
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
View More »
Lima : Hospital Nacional Arzobispo Loayza
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Poland
?Uromin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Bialystok : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Bydgoszcz : Szpital Uniwersytecki im.dr.A.Jurasza w Bydgoszczy Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Chelmno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Chelmno : ZOZ Poradnia Zdrowia Psychicznego Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
View More »
Gdansk : Wojewodzki Szpital Psychiatryczny im. prof. Tadeusza Bilikie Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Gdansk : Klinika Chorob Psychicznych i Zaburzen Nerwicowych GUM Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Gdansk : Klinika Chorob Psychicznych i Zaburzen Nerwicowych GUM Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Gdansk : Wojewodzki Szpital Psychiatryczny im. prof. Tadeusza Bilikie Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Gorlice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Katowice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Kielce : NZOZ Syntonia Poradnia Zdrowia Psychicznego Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Krakow : Sapital Uniwersytecki w Krakowie Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Krakow : Malopolskie Centrum Medyczne Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Leszno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Lublin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Many Locations : Updated
Depression and Fatigue in MS Patients Treated With Betaferon.
Ozimek : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Torun : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Tuszyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Tuszyn : Klinika Psychiatryczna Inventiva Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Puerto Rico
Corozal : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Ponce : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Ponce : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Ponce : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
San Juan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
View More »
San Juan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
San Juan : INSPIRA Clinical Research
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
San Juan : Dharma Institute & Research Center
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Romania
Arad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Bucharest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Bucharest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Focsani : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Iasi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
View More »
Oradea : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Timisoara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Russian Federation
Ekaterinburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Moscow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Moscow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Rostov-On-Don : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Saint Petersburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
View More »
Smolensk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Stavropol : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Tomsk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Serbia
Belgrade : PsychDptClin HospCentre Zvezdara Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Belgrade : Clinical Center Dr Dragisa Misovic Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Belgrade : Institute for Psychiatry, Clinical Centre of Serbia Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Belgrade : Institute of Neuropsychiatry "Dr Laza Lazarevic" Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kragujevac : Clinical Centre Kragujevac Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
View More »
Novi Knezevac : Specialized Hospital for psychiatric diseases- Sveti vracevi Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Slovakia
Banska Bystrica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Bardejov : Centrum zdravia R. B. K. s.r.o.
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Bojnice : Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach Psychiatricke oddelenie Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Bojnice : Bojniciach
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Bojnice : Psychiatricke oddelenie - Nemocnica s poliklinikou Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
View More »
Bratislava : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Bratislava : SK004
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Bratislava : SK006
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Bratislava : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Bratislava : Psychiatricka ambulancia Mentum, s.r.o. Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Bratislava : Univerzitna nemocnica Bratislava, Nemocnica Ruzinov Psychiatricka klinika Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Bratislava : FNsP Bratislava, Nemocnica Ruzinov
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Bratislava : Psychiatricka ambulancia Mentum s.r.o.
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Bratislava : Psychiatricka ambulancia Mentum, s.r.o. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kosice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Liptovsky Mikulas : Nemocnica s poliklinikou Liptovsky Mikulas Psychiatricke oddelenie Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Liptovsky Mikulas : Nemocnica s poliklinikou Liptovsky Milulas
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Michalovce : SK002
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Michalovce : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Rimavska Sobota : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Rimavska Sobota : Psychiatricka ambulancia, PsychoLine s.r.o. Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Rimavska Sobota : PsychoLine s.r.o. Psychiatricka ambulancia Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Rimavska Sobota : PsychoLine s.r.o.
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Rimavska Sobota : Psychiatricka ambulancia, PsychoLine s.r.o. Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Roznava : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Roznava : Psychiatricke oddelenie sv. Barbory Roznava Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Roznava : Nemocnica s poliklinikou sv Barbory Roznava a.s. Psychiatricke oddelenie Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Roznava : Nemocnica s poliklikou Sv. Barbory
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Roznava : Psychiatricke oddelenie sv. Barbory Roznava Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Svidnik : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Svidnik : Centrum zdravia R. B.K. s.r.o. Psychiatricka ambulancia Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Trencin : Pro mente sana, s.r.o., Psychiatricka Ambulancia Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Trencin : Pro mente sana s.r.o. Psychiaricka ambulancia Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Trencin : Pro mente sana
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Trencin : Pro mente sana, s.r.o., Psychiatricka Ambulancia Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Zvolen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
South Africa
Bellville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Cape Town : Cape Trial Centre Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cape Town : Flexivest Fourteen Research Centre Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cape Town : Cape Trial Centre Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cape Town : Knighton Surgery Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
View More »
Cape Town : Flexivest Fourteen Research Centre Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cape Town : Cape Trial Centre Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cape Town : Knighton Surgery Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cape Town : Flexivest Fourteen Research Centre Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Centurion : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Centurion : Vista Clinic Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Centurion : Vista Clinic Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Durban : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
George : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Johannesburg : Dr Magnus & Dr Brink Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Johannesburg : Dr Magnus & Dr Brink Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Paarl : Paarl Medical Centre Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Paarl : Paarl Medical Centre Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Pretoria : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Pretoria : Dey Clinic Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Vereeniging : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
West Cape : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Spain
Alcoy : Hospital Verge dels Lliris de Alcoy Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Arganda Del Rey : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Barcelona : Hospital de l'Esperança Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Barcelona : Hospital Clínic de Barcelona Updated
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Barcelona : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
View More »
Coslada (Madrid) : Hospital del Henares Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Coslada (Madrid) : Hospital del Henares Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Madrid : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Madrid : Hospital Psiquiatrico Dr Rodriguez Lafora Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Oviedo : Centro de Salud Mental Ii "La Corredoria"
Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
Palma De Mallorca : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Pamplona : Clínica Universitaria de Navarra Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Salamanca : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Vitoria : Hospital Santiago Apostol Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Vitoria : Hospital Santiago Apostol Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Vitoria-Gasteiz : Hospital Psiquiátrico de Álava Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Vitoria-Gasteiz : Hospital Psiquiátrico de Álava Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Sweden
Falun : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Goteborg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Halmstad : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Halmstad : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Kungens Kurva : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
View More »
Kungens Kurva : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Lulea : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Lund : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Lund : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Lund : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Malmo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Malmö : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Malmø : SE004
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Solna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Stockholm : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Stockholm : SE001
A Study of 15 and 20 mg of Lu AA21004 in Major Depressive Disorder
Uppsala : Local Institution
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Uppsala : Local Institution
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
Switzerland
Basel : University Hospital Basel
General Practice Research Database Seroquel XR Safety Study
Geneva : Centre de Thérapies Breves (CTB), Secteur Jonction
EScitalopram PIndolol ONset of Action
Taiwan
Taichung : Chung Shan Medical University Hospital
Aripiprazole for the Augmentation of Antidepressant Therapy
Turkey
Adapazari : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Denizli : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Diyarbakir : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Istanbul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Prevention of Re-emergence of Depression Symptoms
Ukraine
Chernihiv District : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Dnipropetrovsk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Dnipropetrovsk : Regional Center of Psychosomatic Pathology of Dnipropetrovsk Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Dnipropetrovsk : Regional Clinical Hospital n.a.l.l. Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Dnipropetrovsk : Com. Inst. "Dnipropetrovsk Reg. Cl. Psych. Hosp." DSMA Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
View More »
Dnipropetrovsk : Com Inst Knipropetrovsk Reg Cl Psych Hospital DSMA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Dnipropetrovsk : Dnipropetrovsk Regional Clinical Hospital named Mechnikov
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Donetsk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Donetsk : Donetsk National Medical University n.a. M. Horkyy Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kharkiv : Public Institution "Institute of Neurology, Psychiatry and N Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kharkiv : St.In."Inst. of Neurol., Psych. and Narcol. of the AMSU" Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Kharkiv : Public Institution "Institute of Neurology, Psychiatry and N Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kharkov : St. In. Inst of Neurol, Psych, and Narcol of the AMSU
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Kherson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Kherson : Kherson Regional Psychiatric Hospital Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Kherson : Kherson Regional Psychiatric Hospital
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Kiev : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Kiev : Kiev City Psychoneurological Hospital N 1, CNTRP Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kiev : Kiev City Psychoneurological Hospital N 1, CNTRP Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Kviv : Kyiv City Psychoneurological Hospital #2 Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Kyiv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Kyiv : Kyiv City Psychoneurological Hospital #2
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Lugansk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Lugansk : Lugansk State Medical University, Department of Psychiatry, Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Lviv : Lviv Reg.St.Cl.Psych.Hosp.Dept.#20, LNMU n.a.D. Halytskiy Chair of Psychiatry, Psychology and Sexololgy Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Lviv : Lviv Regional Clinical Psychiatric Hospital
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Lviv : Danylo Galitsky Lviv State Medical University Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Odessa : Odessa Regional Psychoneurology Dispensary Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Odessa : Odessa Regional Psychoneurology Dispensary Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Poltava : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Poltava : Ukrainian Medical Stomatological Academy, Department of Psyc Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Simferopol : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Simferopol : Crimean State Medical University, Department of Psychiatry, Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Ternopil : Ternopil Regional Municipal Dispensary, Narcology Dept., Ch. of Neurol. Psych. Narcol. & Med. Psychol. Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Ternopil : Ternopil Regional Municipal Dispensary, Narcology Dept.
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Uzhorod : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Vinnytsya : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Vinnytsya : M.I. Pirogov Vinnitsa National Medical University, Departmen Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Zaporizhzhia : Zapor Reg. Cl. Hosp., Zaporizhzhia SMU, ENT Dept. Updated
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Zaporizhzhya : Zapor. Reg. CI Hospital, Zaporizhzhia SMU
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
United Kingdom
Bexhill-On-Sea : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Birmingham : Local Institution
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
Chesterfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Glasgow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
London : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of the Neurobiology of Depression
United States
Washington : Updated
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Washington : US003
Pharmacokinetics and Tolerability of Lu AA21004 in Child and Adolescent Patients With Depressive or Anxiety Disorder
Washington : Forest Investigative Site 008
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Washington DC : Comprehensive NeuroScience Updated
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Washington DC : Comprehensive NeuroScience Updated
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
